We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Nicox annonce la publication de la partie adaptive de l’étude clinique de phase 3 Mont Blanc sur NCX 470 Communiqué de presseNicox annonce la publication de la partie adaptive de l’étude clinique...
Nicox Announces Publication of the Adaptive Design Period of the NCX 470 Mont Blanc Phase 3 Trial Press Release Nicox Announces Publication of the Adaptive Design Period of the NCX 470 Mont Blanc...
Nicox Provides Third Quarter 2024 update and First Half 2024 Financial Results Press Release Nicox Provides Third Quarter 2024 update and First Half 2024 Financial Results Topline results from...
Nicox : Point financier sur le troisième trimestre 2024 et résultats financiers du premier semestre 2024 Communiqué de presseNicox : Point financier sur le troisième trimestre 2024 et résultats...
Nicox et Soleus signent un accord de financement de 16,5 millions de dollars combinant la vente de redevances et un financement en fonds propres Communiqué de presse Nicox et Soleus signent un...
Nicox and Soleus Sign $16.5 million Royalty and Equity Financing Press Release Nicox and Soleus Sign $16.5 million Royalty and Equity Financing Gross proceeds of $15 million (€13.7 million) for...
Nicox et Glaukos signent un accord exclusif de recherche incluant une option de licence mondiale pour NCX 1728 Communiqué de presseNicox et Glaukos signent un accord exclusif de recherche incluant...
Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement Press Release Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement...
Nicox annonce l’approbation de ZERVIATE en Chine Communiqué de presseNicox annonce l’approbation de ZERVIATE en Chine Ocumension Therapeutics, partenaire licencié de Nicox, a reçu l'approbation...
Nicox Announces Approval of ZERVIATE in China Press Release Nicox Announces Approval of ZERVIATE in China Nicox’s partner, Ocumension Therapeutics, has received approval for ZERVIATE® for ocular...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0.22 | 0.225 | 0.206 | 58659 | 0.2163213 | DE |
4 | -0.026 | -10.5691056911 | 0.246 | 0.249 | 0.206 | 67773 | 0.23088379 | DE |
12 | 0.046 | 26.4367816092 | 0.174 | 0.32 | 0.14 | 376496 | 0.25987674 | DE |
26 | -0.139 | -38.7186629526 | 0.359 | 0.36 | 0.14 | 257637 | 0.24500237 | DE |
52 | -0.18 | -45 | 0.4 | 0.4915 | 0.14 | 154907 | 0.2694968 | DE |
156 | -0.362 | -62.1993127148 | 0.582 | 0.65 | 0.14 | 132975 | 0.3208471 | DE |
260 | -0.362 | -62.1993127148 | 0.582 | 0.65 | 0.14 | 132975 | 0.3208471 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions